» Articles » PMID: 23123024

Kinetic and HPV Infection Effects on Cross-type Neutralizing Antibody and Avidity Responses Induced by Cervarix(®)

Overview
Journal Vaccine
Date 2012 Nov 6
PMID 23123024
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We previously demonstrated that Cervarix(®) elicits antibody responses against vaccine-related types for which clinical efficacy was demonstrated (HPV-31 and -45). Here, we evaluated the kinetics of neutralization titers and avidity of Cervarix(®)-induced antibodies up to 36 months of follow-up in unexposed and HPV infected women.

Methods: A subset of women who participated in the Cost Rica HPV-16/18 Vaccine Trial had pre- and post-vaccination sera tested for antibody responses to HPV-16, -18, -31, -45, and -58 using a pseudovirion-based neutralization assay, and HPV-16 antibody avidity using an HPV-16 L1 VLP (virus-like particle)-based ELISA developed in our laboratory.

Results: In uninfected women, neutralizing antibody titers did not reach significance until after the 3rd dose for HPV-31 (month 12, p=0.009) and HPV-45 (month 12, p=0.003), but then persisted up to month 36 (HPV-31, p=0.01; HPV-45, p=0.002). Individuals infected with HPV-16 or HPV-31 at enrollment developed a significantly higher median antibody response to the corresponding HPV type after one dose, but there was not a difference between median titers after three doses compared to the HPV negative group. Median HPV-16 antibody avidity and titer increased over time up to month 12; however, the HPV-16 avidity did not correlate well with HPV-16 neutralizing antibody titers at each time point examined, except for month 6. The median avidity levels were higher in HPV-16 infected women at month 1 (p=0.04) and lower in HPV-16 infected women at month 12 (p=0.006) compared to the HPV negative women.

Conclusions: The persistence of cross-neutralization titers at month 36 suggests cross-reactive antibody responses are likely to persist long-term and are not influenced by infection status at enrollment. However, the weak correlation between avidity and neutralization titers emphasizes the need for examining avidity in efficacy studies to determine if high avidity antibodies play a critical role in protection against infection.

Citing Articles

Distribution of high- and low-risk human papillomavirus genotypes and their prophylactic vaccination coverage among West African women: systematic review.

Ouedraogo R, Kande A, Nadembega W, Ouermi D, Zohoncon T, Djigma F J Egypt Natl Canc Inst. 2023; 35(1):39.

PMID: 38060078 DOI: 10.1186/s43046-023-00196-x.


Optimization of a protocol for the evaluation of antibody responses to human papillomavirus (HPV) vaccination in low-resource settings.

Donkoh E, Dassah E, Owusu-Dabo E BMC Womens Health. 2022; 22(1):234.

PMID: 35710373 PMC: 9204889. DOI: 10.1186/s12905-022-01821-y.


Immunity after HPV Vaccination in Patients after Sexual Initiation.

Pruski D, Lagiedo-Zelazowska M, Millert-Kalinska S, Sikora J, Jach R, Przybylski M Vaccines (Basel). 2022; 10(5).

PMID: 35632487 PMC: 9144159. DOI: 10.3390/vaccines10050728.


HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial.

Tsang S, Schiller J, Porras C, Kemp T, Herrero R, Schussler J NPJ Vaccines. 2022; 7(1):40.

PMID: 35351898 PMC: 8964739. DOI: 10.1038/s41541-022-00431-x.


Prevalence of vaccine and non-vaccine human papillomavirus types among women in Accra and Kumasi, Ghana: a cross-sectional study.

Debrah O, Agyemang-Yeboah F, Donkoh E, Asmah R BMC Womens Health. 2021; 21(1):372.

PMID: 34702246 PMC: 8549380. DOI: 10.1186/s12905-021-01511-1.


References
1.
Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

2.
ROOST H, Bachmann M, Haag A, Kalinke U, Pliska V, Hengartner H . Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity. Proc Natl Acad Sci U S A. 1995; 92(5):1257-61. PMC: 42498. DOI: 10.1073/pnas.92.5.1257. View

3.
de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

4.
Kreimer A, Rodriguez A, Hildesheim A, Herrero R, Porras C, Schiffman M . Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst. 2011; 103(19):1444-51. PMC: 3186781. DOI: 10.1093/jnci/djr319. View

5.
Safaeian M, Ghosh A, Porras C, Lin S, Rodriguez A, Schiffman M . Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev. 2012; 21(9):1547-54. DOI: 10.1158/1055-9965.EPI-12-0558. View